Study of Zymfentra for people with Crohn's or colitis
Part of Digestive system clinical trials.
This study follows adults with inflammatory bowel disease who are starting or switching to Zymfentra. Researchers will track your health over the next year to see how the medicine works in real life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have Crohn's disease, ulcerative colitis, or unclassified IBD
- You are either starting Zymfentra after your first few infusions of another infliximab, or you are switching from an infliximab you've been taking regularly to Zymfentra
- Your doctor plans to follow you at this center for at least the next 12 months
- Your IBD diagnosis is confirmed by symptoms and tests like a colonoscopy, X-ray, or biopsy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether closely monitoring and adjusting infliximab (a biologic medicine) can help people hospitalized with a moderate-to-severe flare of Crohn's disease, ulcerative colitis, or unclassified inflammatory bowel disease who haven't gotten better with IV steroids. The goal is to improve treatment response and outcomes.
This study tests a new medicine called mirikizumab for people with ulcerative colitis or Crohn's disease who have not responded well to other treatments. It aims to see if mirikizumab can help control symptoms and improve quality of life.
This study tests a medicine called tirzepatide to see if it can help people with active Crohn’s disease who have not responded to multiple prior treatments. It focuses on how the drug might work beyond just reducing inflammation.
This study follows adults with moderate-to-severe Crohn's disease or ulcerative colitis who are starting treatment with guselkumab (Tremfya). It aims to see how well the medication works and how long the effects last over time.
This trial tests whether a person's genetic makeup affects how well infliximab works for treating Crohn's disease. It may help doctors predict which patients benefit most from this medication.
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
Hear when a new Indeterminate Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.